16
Apr
Bisphosphonate Related Osteonecrosis Of The Jaw Treatment. The diagnosis is primarily clinical. Since first being reported by Marx in 2003 1 bisphosphonate-related osteonecrosis of the jaw BRONJ a severe side effect of bisphosphonates has been a growing concern for oral and maxillofacial surgeons. Further research is needed to determine the. In recent years however bisphosphonate-related osteonecrosis of the jaw BRONJ has been a rare but major complication of this therapy.
The diagnosis is primarily clinical. And as part of some cancer regimens. Individual bisphosphonates have different indications and are used for. It is characterised by an avascular area of necrotic bone in the maxillofacial area with or without exposed bone that does not heal within 8 weeks in a patient who has no oral cancer or history of prior radiation therapy to the craniofacial region 3 4. The main groups of drugs involved are anti-resorptive drugs and anti-angiogenic drugs. Bisphosphonates BPs have been used for the management of bone metabolic diseases.
Evid Based Dent 18 56 2017.
Currently their therapeutic use has increased as also have their adverse effects one of the most important being the bisphosphonate-related osteonecrosis of the jaw BRONJ a complication of diffi cult treatment. Individual bisphosphonates have different indications and are used for. 2 current or previous treatment with bisphosphonates. Total Denture Bisphosphonate-Related Osteonecrosis of the Jaw-BRONJ is a severe complication in the. Evaluation for potential risk factors before implementing bisphosphonate treatment is indicated and serial oral examinations during treatment are imperative. In recent years however bisphosphonate-related osteonecrosis of the jaw BRONJ has been a rare but major complication of this therapy.